A Rapidly Expanding Library of Rare Single Cell Applications
These application areas represent just a few of the ways in which the RareCyte platform is enabling new applications or dramatically enhancing existing applications.
Beyond flow cytometry – enabling applications that flow cytometry cannot reach
Cyclic Immunofluorescence. CycIF is a method for profiling circulating human leukocytes with highly-multiplexed cyclic immunofluorescence microscopy. The method has distinct advantages over flow cytometry in that it has greater sensitivity for rare cell populations, allows for repeat analysis and long-term storage of precious biological samples, and obviates the need for spectral deconvolution.
Rare immune cells play a critical role in many diseases, including cancer
Merkel Cell Carcinoma. MCC is a rare but aggressive form of skin cancer that has proved problematic for analysis by conventional flow cytometry. RareCyte’s CytePicker® technology has enabled RT-PCR analysis of single antigen-specific CD4 cells, delivering information that is clearer and more detailed that obtainable by flow cytometry.
Non-invasive genetic testing of fetal cells in maternal blood
RareCyte technology brings a new level of sensitivity and detail to the genetic analysis of fetal cells. Although other noninvasive methods for genetic testing are currently widely available, such as cell-free fetal DNA testing, they have their limitations. For instance, cell-free DNA testing cannot reliably detect very small changes in the fetal genome, in particular gene deletions that can lead to devastating diseases.
Research on the genetic analysis of rare fetal cells in maternal blood was published in Prenatal Diagnosis.
Infectious Disease Testing
Lyme disease – a case of extremely rare infectious agents
Lyme Disease is now the most common arthropod-borne illness in the U.S., with more than 300,000 cases reported to the Centers for Disease Control and Prevention [CDC] every year. Diagnosis and treatment of Lyme Disease can be challenging for clinicians due to its diverse manifestations and the limitations of currently available serological (blood) tests. The extreme sensitivity of the RareCyte platform offers the possibility of accurate diagnosis in the early stages of the disease.